(Bloomberg) — A boon to Sanofi’s profit and sales from the coronavirus outbreak will be short-lived as the pandemic hinders the drugmaker’s efforts to get some medicines to patients.The sales burst of the first quarter, when patients stocked up on diabetes and rare-disease medicines ahead of lockdowns, is waning, the Paris-based company said Friday. The pharma giant attributed about half of its 16% profit gain to Covid-19.Sanofi’s report also hinted at a worrisome trend that doctors have warned about: new patients not getting treatment for their ailments in the era of Covid-19.There was a decline in new patients with multiple …read more
Source:: Yahoo Finance
